8 documents

Read All
17:33 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma; pancreatic cancer In vitro and mouse studies identified an amiloride-based PLAU inhibitor that could help treat metastatic fibrosarcoma and pancreatic cancers. Chemical synthesis and in vitro testing of amiloride analogs in enzyme activity...
Read More
18:09 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture studies suggest inhibiting KIF15 alone or in combination with KSP could help treat cancer. In HeLa cells, a tool compound KIF15 inhibitor decreased proliferation compared with no treatment, and the KIF15...
Read More
07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ring finger protein 20 (RNF20); RNF40; kinesin spindle protein (KSP; Eg5; KIF11)

Cancer INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting RNF20 , RNF40 or KSP could help treat breast cancer. In a human breast adenocarcinoma cell line, siRNA targeting RNF20, RNF40 or KSP increased...
Read More
07:00 , Jun 6, 2016 |  BC Week In Review  |  Company News

4SC, Link Health deal

4SC granted Link Health exclusive rights to develop and commercialize 4SC-205 in Taiwan and China, including Hong Kong and Macau. Link Health will be responsible for clinical development of the oral inhibitor of kinesin spindle...
Read More
01:19 , Jun 1, 2016 |  BC Extra  |  Company News

Link gets China rights to 4SC cancer candidate

4SC AG (Xetra:VSC) granted Link Health Group (Guangzhou, China) exclusive rights to oncology candidate 4SC-205 in China, Hong Kong, Taiwan and Macau. Link Health will be responsible for clinical development of the oral inhibitor of...
Read More
07:00 , Mar 14, 2016 |  BioCentury  |  Politics, Policy & Law

Value demonstration

Acting Administrator Andy Slavitt is pitting CMS against oncologists, hospitals, the pharmaceutical industry and congressional Republicans with a proposal to conduct a massive, nationwide controlled experiment testing value-based payments for drugs provided through Medicare Part...
Read More
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Wilex, RedHill deal

Wilex granted RedHill exclusive rights to develop and commercialize Mesupron outside of Taiwan and China, including Hong Kong and Macau. Wilex will receive $1 million up front and is eligible for tiered royalties from the...
Read More
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Link Health, Wilex deal

Wilex granted Link Health exclusive rights to develop and commercialize Mesupron in Taiwan and China, including Hong Kong and Macau, for all cancer indications. Wilex is eligible for an upfront payment and milestones totaling more...
Read More